StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

Equities research analysts at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the stock.

Separately, Piper Sandler reiterated an “overweight” rating and issued a $4.50 target price on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Stock Up 0.0 %

Shares of NSPR stock opened at $2.48 on Friday. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.67. The firm’s 50 day moving average price is $2.65 and its two-hundred day moving average price is $2.56. The stock has a market cap of $61.83 million, a price-to-earnings ratio of -3.35 and a beta of 0.93.

InspireMD (NYSE:NSPR) last posted its earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. The business had revenue of $1.74 million for the quarter, compared to analyst estimates of $1.74 million. During the same quarter in the previous year, the firm posted ($0.24) EPS. On average, equities analysts forecast that InspireMD will post -0.82 EPS for the current fiscal year.

Institutional Trading of InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC purchased a new stake in InspireMD, Inc. (NYSE:NSPR) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned about 0.74% of InspireMD as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.